Developing, licensing and commercializing cannabinoid based medications for specific medical conditions and disorders. Our drug development activities are undertaken in accordance with Food and Drug Administration (FDA) or comparable development pathways in other countries.
Our intent is that any medications we develop will be physician prescribed.
The development and licensing of proprietary delivery systems for cannabinoid medications. In addition to the Company’s precision parenteral formulations, the Company’s advanced tablet technology provides for the accurate oral and sublingual dosing of cannabinoid API’s with our without adjunct API’s for both human (PerfectDose™) and veterinary applications (Triit™).
Investments in companies, and the acquisition of technologies, or medications, focused on cannabinoid-based research, through Special Purpose Vehicles (SPV) controlled by Nexien BioPharma Inc.